ArticleCancer medicine2026
When Timing Matters Most: Early Relapse Outweighs Baseline Risk in Myeloma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma outcomes vary widely, with risk stratification typically based on baseline characteristics. Functionally high-risk multiple myeloma (FHRMM), defined by early relapse within 12 months of initial therapy or autologous stem cell transplant, is associated with poor prognosis. However, the continued prognostic impact of baseline high-risk features within the FHRMM cohort remains unclear. This study analyzed 181 FHRMM patients from the CoMMpass dataset, categorized into standard-risk (SRG) and high-risk (HRG) groups based on baseline cytogenetics and ISS stage. Despite SRG patients possessing more favorable baseline risk profiles, including lower SKY92 scores, their overall survival (OS) was not significantly different from HRG patients (20.7 vs. 18.1 months, p = 0.059). Treatment regimens and response rates were comparable between groups. Within the FHRMM cohort, only baseline ISS stage I retained prognostic significance for OS. In conclusion, FHR status overrides traditional baseline risk factors in determining prognosis. Patients experiencing early relapse should be considered uniformly high-risk, highlighting the need for effective salvage therapies and consideration of novel treatments like CAR T-cell therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.